Literature DB >> 19687098

Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis.

Katherine A McLaughlin1, Tanuja Chitnis, Jia Newcombe, Bettina Franz, Julia Kennedy, Shannon McArdel, Jens Kuhle, Ludwig Kappos, Kevin Rostasy, Daniela Pohl, Donald Gagne, Jayne M Ness, Silvia Tenembaum, Kevin C O'Connor, Vissia Viglietta, Susan J Wong, Norma P Tavakoli, Jerome de Seze, Zhannat Idrissova, Samia J Khoury, Amit Bar-Or, David A Hafler, Brenda Banwell, Kai W Wucherpfennig.   

Abstract

Multiple sclerosis (MS) typically manifests in early to mid adulthood, but there is increasing recognition of pediatric-onset MS, aided by improvements in imaging techniques. The immunological mechanisms of disease are largely unexplored in pediatric-onset MS, in part because studies have historically focused on adult-onset disease. We investigated autoantibodies to myelin surface Ags in a large cohort of pediatric MS cases by flow cytometric labeling of transfectants that expressed different myelin proteins. Although Abs to native myelin oligodendrocyte glycoprotein (MOG) were uncommon among adult-onset patients, a subset of pediatric patients had serum Abs that brightly labeled the MOG transfectant. Abs to two other myelin surface Ags were largely absent. Affinity purification of MOG Abs as well as competition of binding with soluble MOG documented their binding specificity. Such affinity purified Abs labeled myelin and glial cells in human CNS white matter as well as myelinated axons in gray matter. The prevalence of such autoantibodies was highest among patients with a very early onset of MS: 38.7% of patients less than 10 years of age at disease onset had MOG Abs, compared with 14.7% of patients in the 10- to 18-year age group. B cell autoimmunity to this myelin surface Ag is therefore most common in patients with a very early onset of MS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19687098      PMCID: PMC2795331          DOI: 10.4049/jimmunol.0801888

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  58 in total

Review 1.  Driver clones and determinant spreading.

Authors:  E E Sercarz
Journal:  J Autoimmun       Date:  2000-06       Impact factor: 7.094

2.  Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children.

Authors:  R C Dale; C de Sousa; W K Chong; T C Cox; B Harding; B G Neville
Journal:  Brain       Date:  2000-12       Impact factor: 13.501

3.  Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations.

Authors:  A Rivera; C C Chen; N Ron; J P Dougherty; Y Ron
Journal:  Int Immunol       Date:  2001-12       Impact factor: 4.823

4.  The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls.

Authors:  C G Haase; J Guggenmos; U Brehm; M Andersson; T Olsson; M Reindl; J M Schneidewind; U K Zettl; F Heidenreich; T Berger; H Wekerle; R Hohlfeld; C Linington
Journal:  J Neuroimmunol       Date:  2001-03-01       Impact factor: 3.478

Review 5.  Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.

Authors:  H C von Büdingen; N Tanuma; P Villoslada; J C Ouallet; S L Hauser; C P Genain
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

6.  Early onset multiple sclerosis: a longitudinal study.

Authors:  A Boiko; G Vorobeychik; D Paty; V Devonshire; D Sadovnick
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

7.  Anti-myelin oligodendrocyte glycoprotein B-cell responses in multiple sclerosis.

Authors:  A Kennel De March; M De Bouwerie; M N Kolopp-Sarda; G C Faure; M C Béné; C C A Bernard
Journal:  J Neuroimmunol       Date:  2003-02       Impact factor: 3.478

8.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

9.  Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients.

Authors:  Silvia Tenembaum; Nestor Chamoles; Natalio Fejerman
Journal:  Neurology       Date:  2002-10-22       Impact factor: 9.910

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  70 in total

Review 1.  Multiple sclerosis.

Authors:  Alyssa Nylander; David A Hafler
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

2.  Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.

Authors:  Marie Cathrin Mayer; Edgar Meinl
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

Review 3.  Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs.

Authors:  Xiao-Fang Liu; Yue-Bei Luo; Zhao-Hui Luo; Huan Yang
Journal:  Neurochem Res       Date:  2014-07-29       Impact factor: 3.996

4.  Clinical and MRI phenotype of children with MOG antibodies.

Authors:  Cristina Fernandez-Carbonell; David Vargas-Lowy; Alexander Musallam; Brian Healy; Katherine McLaughlin; Kai W Wucherpfennig; Tanuja Chitnis
Journal:  Mult Scler       Date:  2015-06-03       Impact factor: 6.312

5.  White matter disease: Roles of anti-MOG antibodies in demyelinating diseases.

Authors:  Tomas Olsson
Journal:  Nat Rev Neurol       Date:  2011-04-12       Impact factor: 42.937

Review 6.  Therapies for multiple sclerosis: considerations in the pediatric patient.

Authors:  Brenda Banwell; Amit Bar-Or; Gavin Giovannoni; Russell C Dale; Marc Tardieu
Journal:  Nat Rev Neurol       Date:  2011-01-11       Impact factor: 42.937

7.  Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease.

Authors:  Shahd H M Hamid; Dan Whittam; Mariyam Saviour; Amal Alorainy; Kerry Mutch; Samantha Linaker; Tom Solomon; Maneesh Bhojak; Mark Woodhall; Patrick Waters; Richard Appleton; Martin Duddy; Anu Jacob
Journal:  JAMA Neurol       Date:  2018-01-01       Impact factor: 18.302

Review 8.  B cells in multiple sclerosis: connecting the dots.

Authors:  H-Christian von Büdingen; Amit Bar-Or; Scott S Zamvil
Journal:  Curr Opin Immunol       Date:  2011-10-07       Impact factor: 7.486

Review 9.  Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.

Authors:  Amy Waldman; Angelo Ghezzi; Amit Bar-Or; Yann Mikaeloff; Marc Tardieu; Brenda Banwell
Journal:  Lancet Neurol       Date:  2014-09       Impact factor: 44.182

10.  Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis.

Authors:  Keith Van Haren; Beren H Tomooka; Brian A Kidd; Brenda Banwell; Amit Bar-Or; Tanuja Chitnis; Silvia N Tenembaum; Daniela Pohl; Kevin Rostasy; Russell C Dale; Kevin C O'Connor; David A Hafler; Lawrence Steinman; William H Robinson
Journal:  Mult Scler       Date:  2013-04-23       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.